Can you provide the consensus rating for Progenics Pharmaceuticals stock?
The consensus rating for Progenics Pharmaceuticals (PGNX) is 100 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Progenics Pharmaceuticals (PGNX) Forecast, Price Target & Analyst Ratings
NASDAQ:PGNX
Current stock price
4.1
-0.43 (-9.39%)
At close:
4.33
+0.23 (+5.61%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Progenics Pharmaceuticals (PGNX).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $4.10 to mean target of N/A, Based on 1 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
100.00%
PGNX was analyzed by 1 analysts. The buy percentage consensus is at 100. So analysts seem to be very confident about PGNX.
In the previous month the buy percentage consensus was at a similar level.
Only 1 analysts analyzed PGNX. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A